Equities

Airway Medix SA

Airway Medix SA

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Airway Medix SA had revenues fall -87.37% from 95.00k to 12.00k, though the company grew net income from a loss of 37.91m to a smaller loss of 3.28m.
Gross margin19.05%
Net profit margin-43,861.91%
Operating margin-18,252.38%
Return on assets-203.45%
Return on equity--
Return on investment--
More ▼

Cash flow in PLNView more

In 2023, Airway Medix SA increased its cash reserves by 65,400.00%, or 654.00k. Cash Flow from Financing totalled 4.85m or 40,400.00% of revenues. In addition the company used 4.20m for operations while cash from investing was breakeven.
Cash flow per share-0.1369
Price/Cash flow per share--
Book value per share-0.272
Tangible book value per share-0.272
More ▼

Balance sheet in PLNView more

Airway Medix SA uses little or no debt in its capital structure.
Current ratio0.0208
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.